Patents by Inventor Gerald D. Hurst

Gerald D. Hurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5849482
    Abstract: Oligonucleotides (ODNs) include a sequence that is complementary to a target sequence in single stranded RNA, or single or double stranded DNA, and an alkylating function which after hybridization alkylates the target sequence. ODNs adapted for alkylating single stranded RNA, such as messenger RNA, are complementary to the target sequence in the Watson Crick sense. ODNs adapted for alkylating double stranded DNA have at least two alkylating functions and are complementary to the target sequence in the Hoogsteen or reverse Hoogsteen sense. With these ODNs both strands of the target sequence are alkylated. A third class of ODNs have at least approximately 26 nucleotide units in a continous sequence which are complementary to the target sequence of double stranded DNA, and the alkylating function is covalently attached to a nucleotide unit in the continuous sequence. Alkylation or cross-linking with this class of ODNs occurs in the presence of a recombinase enzyme.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Igor V. Kutyavin, Alexander A. Gall, Charles R. Petrie, John C. Tabone, Gerald D. Hurst
  • Patent number: 5824796
    Abstract: This invention is directed to novel substituted nucleotide bases with a crosslinking arm which accomplish crosslinking between specific sites on adjoining strands of oligonucleotides or oligodeoxynucleotides. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel oligonucleotides for diagnostic and therapeutic purposes. The crosslinking agents of the invention are of the following formula (I'):R.sub.1 --B--(CH.sub.2).sub.q --(Y).sub.r --(CH.sub.2).sub.m --A'(I')wherein,R.sub.1 is hydrogen, or a sugar moiety or analog thereof optionally substituted at its 3' or its 5' position with a phosphorus derivative attached to the sugar moiety by an oxygen and including groups Q.sub.1 Q.sub.2 and Q.sub.3 or with a reactive precursor thereof suitable for nucleotide bond formation;Q.sub.1 is hydroxy, phosphate or diphosphate;Q.sub.2 is .dbd.O or .dbd.S;Q.sub.3 is CH.sub.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: October 20, 1998
    Assignee: EPOCH Pharmaceuticals, Inc.
    Inventors: Charles R. Petrie, Rich B. Meyer, John C. Tabone, Gerald D. Hurst
  • Patent number: 4701545
    Abstract: Esters of .alpha.,.alpha.-haloalkyl boronic acids are prepared by the addition of an alkali metal dialkylamide, or some other equivalent sterically hindered base to a mixture of a 1,1-dihaloalkane and a trialkyl borate in an organic solvent at a temperature between about -78.degree. C. and +25.degree. C. In one embodiment, diisopropyl (dichloromethyl)borate is formed by the addition of lithium diisopropylamide to a mixture of dichloromethane and triisopropyl borate in the presence of tetrahydrofuran as the solvent medium at a temperature between about -10.degree. C. and +10.degree. C.
    Type: Grant
    Filed: February 12, 1986
    Date of Patent: October 20, 1987
    Assignee: Washington State University Research Foundation, Inc.
    Inventors: Donald S. Matteson, Gerald D. Hurst
  • Patent number: RE38416
    Abstract: This invention is directed to novel substituted nucleotide bases with a crosslinking arm which accomplish crosslinking between specific sites on adjoining strands of oligonucleotides a oligodeoxynucleotides. The invention is also directed to oligonucleotides comprising at least one of these crosslinking agents and to the use of the resulting novel oligonucleotides for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: February 3, 2004
    Assignee: Epoch Biosciences, Inc.
    Inventors: Charles R. Petrie, Rich B. Meyer, John C. Tabone, Gerald D. Hurst